These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 24970869

  • 1. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.
    Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM.
    Clin J Am Soc Nephrol; 2014 Sep 05; 9(9):1620-6. PubMed ID: 24970869
    [Abstract] [Full Text] [Related]

  • 2. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
    Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D.
    Kidney Int; 2003 Apr 05; 63(4):1483-90. PubMed ID: 12631365
    [Abstract] [Full Text] [Related]

  • 3. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A, Serio V, Pota A, Memoli B, Andreucci VE.
    J Nephrol; 2009 Apr 05; 22(1):59-68. PubMed ID: 19229819
    [Abstract] [Full Text] [Related]

  • 4. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.
    Martin KJ, González EA, Gellens ME, Hamm LL, Abboud H, Lindberg J.
    Am J Kidney Dis; 1998 Oct 05; 32(2 Suppl 2):S61-6. PubMed ID: 9808145
    [Abstract] [Full Text] [Related]

  • 5. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ, Bravo Soto JA, Merino Pérez MJ, González Carmelo I, López Jiménez V, García Álvarez T, Acosta Martínez Y, Mazuecos Blanca MA.
    Nefrologia; 2015 Oct 05; 35(4):363-73. PubMed ID: 26306956
    [Abstract] [Full Text] [Related]

  • 6. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
    Llach F, Yudd M.
    Am J Kidney Dis; 2001 Nov 05; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
    [Abstract] [Full Text] [Related]

  • 7. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
    Jamaluddin EJ, Gafor AH, Yean LC, Cader R, Mohd R, Kong NC, Shah SA.
    Clin Exp Nephrol; 2014 Jun 05; 18(3):507-14. PubMed ID: 23903802
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
    Roggeri DP, Mazzaferro S, Brancaccio D, Cannella G, Messa P, Di Luca M, Morosetti M, Costanzo AM, di Luzio Paparatti U, Cornago D, Cozzolino M, FARO Study Group.
    J Med Econ; 2012 Jun 05; 15(6):1110-7. PubMed ID: 22702445
    [Abstract] [Full Text] [Related]

  • 15. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M, Brancaccio D.
    Expert Opin Pharmacother; 2008 Apr 05; 9(6):947-54. PubMed ID: 18377338
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ, Solak Y, Atalay H, Turkmen K, Altintepe L.
    Ren Fail; 2012 Apr 05; 34(3):297-303. PubMed ID: 22251408
    [Abstract] [Full Text] [Related]

  • 17. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.
    Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, Ahmadzadeh S.
    Am J Kidney Dis; 2012 Jan 05; 59(1):58-66. PubMed ID: 21885174
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of the Pharmacological Effects of Paricalcitol Versus Calcitriol on Secondary Hyperparathyroidism in the Dialysis Population.
    Večerić-Haler Ž, Romozi K, Antonič M, Benedik M, Ponikvar JB, Ponikvar R, Knap B.
    Ther Apher Dial; 2016 Jun 05; 20(3):261-6. PubMed ID: 27312912
    [Abstract] [Full Text] [Related]

  • 20. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
    Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM.
    Am J Kidney Dis; 2006 Feb 05; 47(2):263-76. PubMed ID: 16431255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.